Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1286 - Prognostic Impact of Hepatitis B Virus (HBV) Infection in Advanced Intrahepatic Cholangiocarcinoma (iCCA) Patients (pts) Treated with First-line Gemcitabine Plus Cisplatin (GEMCIS)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Hepatobiliary Cancers


Eojin Kim


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


E. Kim, H. Cho, C. Yoo, K. Kim, H. Chang, B. Ryoo

Author affiliations

  • Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR


Abstract 1286


HBV infection is a well-known risk factor of iCCA. However, its prognostic impact has rarely been investigated in pts with advanced iCCA who received chemotherapy.


Between April 2010 and May 2015, a total of 296 pts with histologically documented advanced iCCA received first-line GEMCIS in Asan Medical Center, Seoul, Korea, and were included in this retrospective analysis. Primary endpoint was overall survival (OS). In the multivariate analysis, variables which showed potential association with survival (p 


Median age was 59 years (range, 27-78), and 62 (20.9%) pts with hepatitis B surface antigen positive formed the HBV group. Initially metastatic disease was the most common disease status at the time of GEMCIS (n = 184, 62.2%) followed by recurrence after curative surgery (n = 69, 23.3%) and locally advanced unresectable disease (n = 43, 14.5%). In comparison with the non-HBV group, HBV group were related with young age (mean age 56.4 vs 60.0), male predominance (74.2% vs 57.3%), lower rates of elevated CA 19-9 (42.0% vs 68.5%) and alkaline phosphatase (42.6% vs 60.5%) (p 


Our results suggest that HBV infection might be an independent poor prognostic factor in pts with advanced iCCA treated with first-line GEMCIS. Further translational research is needed to define the differences in the molecular phenotypes between HBV- and non-HBV-associated iCCA.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center, University of Ulsan College of Medicine




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.